U.S., Feb. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07409454) titled 'MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma' on Dec. 09, 2025.
Brief Summary: This is a prospective, single-arm clinical study designed to evaluate the efficacy and safety of the BCMA/CD3 bispecific antibody (CM336) as maintenance therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.
Study Start Date: March 01
Study Type: INTERVENTIONAL
Condition:
Multiple Myeloma
Intervention:
DRUG: anti-BCMA/CD3 bispecific antibody
Anti-BCMA/CD3 bispecific antibody (CM336) will be administered via a subcutaneou...